TICKERNERD
Menu
IMVTIMVTHealthcare · Biotechnology

IMVT Stock Forecast: Immunovant, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$29
+2.54% on the day

The 17 Wall Street analysts covering Immunovant, Inc. hold a median 12-month price target of $49 — +66.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 21 Oct 2026 — in the lower half.

Market cap
$5.9B
Ticker Nerd rank
40/ 100
Median analyst target
$49
Analysts covering
17
Revenue$0.0
Operating income−$160.3M
Net income−$153.2M
Free cash flow−$124.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.8%
1M
−22.0%
YTD
+14.5%
1Y
+54.0%
From 52W high
−35.3%
From 52W low
+55.3%
$19
$45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMVT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immunovant, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
86
Volatility
81
Value
71
Accruals
49
Growth
47
Issuance
36
Quality
35
Revisions
31
Size
21

Momentum (86): The shares have been drifting up relative to others.

Revisions (31): Analysts have, on balance, been cutting their forecasts.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMVT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMVT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26IMVTHigh $66Median $49Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
13 Buy4 Hold0 Sell
Low $30Median $49High $66

The green dot is the last close — the median target sits +66.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Aug 2026JP MorganMaintainsOverweight$47 → $50
30 June 2026CitigroupMaintainsBuy$57 → $61
30 June 2026CitigroupMaintainsBuy—
26 May 2026GuggenheimMaintainsBuy—
22 May 2026Truist SecuritiesMaintainsHold—
21 May 2026B of A SecuritiesMaintainsBuy—
21 May 2026HC Wainwright & Co.MaintainsBuy—
15 Apr 2026Goldman SachsMaintainsNeutral—
20 Mar 2026BernsteinInitiatesMarket Perform—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Feb 2026GuggenheimMaintainsBuy—
8 Jan 2026Truist SecuritiesMaintainsHold—
6 Jan 2026Wolfe ResearchUpgradeOutperform—
15 Dec 2025Goldman SachsMaintainsNeutral—
14 Oct 2025Truist SecuritiesInitiatesHold—
30 Sept 2025JP MorganMaintainsOverweight—
4 Sept 2025HC Wainwright & Co.ReiteratesBuy—
12 Aug 2025B of A SecuritiesMaintainsBuy—
12 Aug 2025JP MorganMaintainsOverweight—
28 July 2025UBSMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IMVT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

IMVT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Immunovant, Inc. returned +54.0% against +15.6% for the S&P 500, dividends included.

IMVT vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26IMVTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMVT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Immunovant, Inc. (IMVT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.3×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
8.0×

Cheaper than 11% of US stocks

EV / EBITDA
−9.0×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−80.1%

Higher than 16% of US stocks

Return on assets
−46.7%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Immunovant, Inc. (IMVT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immunovant, Inc. has a market value of $5.9B and an enterprise value of $5.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$538.2M.

  • Diluted earnings per share, trailing twelve months: $−2.82.

  • Free cash flow in the twelve months to 30 June 2026: −$414.3M.

  • Shares outstanding: 206.3M.

  • Trailing P/E: −10.3×; forward P/E: −10.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Immunovant, Inc. employs 315 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

IMVT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMVTImmunovant, Inc.$5.9B40
MANEVeradermics, Inc.$5.6B3
CGONCG Oncology, Inc.$5.5B19
MIRMMirum Pharmaceuticals, Inc.$5.4B67
COGTCogent Biosciences, Inc.$5.4B32
RYTMRhythm Pharmaceuticals, Inc.$6.1B90
ORKAOruka Therapeutics, Inc.$5.3B37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immunovant, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMVT news & analysis

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

GlobeNewsWire · 21 Oct 2026neutral

Immunovant said it will report financial results for the quarter ended September 30, 2026, before market open on November 9, 2026. Roivant will host a conference call and webcast at 8:00 a.m. ET that day, including an Immunovant business update.

Why it matters — IMVT watchers can expect the company’s quarterly results and business update on November 9.

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

PRNewsWire · 25 Sept 2026negative

SueWallSt has notified investors of a pending investigation into potential securities law violations concerning Immunovant (IMVT). This follows the company's stock falling roughly 6% to a more-than-three-month low on September 23, 2026, after the IMVT-1402 cutaneous lupus study missed its primary endpoint.

Why it matters — IMVT watchers would care because the failed clinical trial outcome, the resulting share-price drop, and the pending securities investigation raise scrutiny around the company's disclosures and its lead drug candidate's prospects.

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down

Zacks Investment Research · 24 Sept 2026negative

Immunovant's IMVT-1402 missed its primary endpoint in a cutaneous lupus erythematosus (CLE) trial, leading the company to halt the CLE program despite positive trends and a favorable safety profile. The news weighed on the stock.

Why it matters — The discontinuation of the CLE program removes potential value from Immunovant's pipeline and could raise questions about IMVT-1402's prospects in other indications.

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

GlobeNewsWire · 23 Sept 2026negative

Immunovant reported topline results from the proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus. The study did not achieve statistical significance on its primary endpoint, and while positive trends and favorable safety data were observed, it did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE. Other clinical development timelines remain on track.

Why it matters — This indicates IMVT-1402 will not be advanced in cutaneous lupus erythematosus, removing a potential indication from Immunovant's pipeline even as other programs continue.

FAQ

Frequently asked questions about IMVT stock

What is the IMVT stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Immunovant, Inc. have a median 12-month price target of $49, with estimates ranging from $30 to $66. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMVT stock a buy right now?

Of the 17 analysts covering Immunovant, Inc., 13 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunovant, Inc. 40 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMVT?

As at 21 Oct 2026, Immunovant, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (86 of 100).

Will IMVT stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +66.7% from the last close, and Ticker Nerd's factor model ranks Immunovant, Inc. 40 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMVT stock forecast for 2030?

No analyst covering Immunovant, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $66 over the next 12 months.

How has IMVT stock performed over the past year?

Immunovant, Inc. returned +54.0% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immunovant, Inc. do?

Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases.

What is the latest news on IMVT?

The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026". Immunovant said it will report financial results for the quarter ended September 30, 2026, before market open on November 9, 2026. Roivant will host a conference call and webcast at 8:00 a.m. ET that day, including an Immunovant business update.

Company

About Immunovant, Inc.

Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. The company’s current work centers on antibody-based treatments that inhibit the neonatal Fc receptor, a mechanism designed to lower harmful IgG autoantibodies involved in multiple immune-mediated conditions. Its pipeline includes investigational programs such as IMVT-1402 and batoclimab, which are being studied across diseases including myasthenia gravis, thyroid eye disease, Graves’ disease, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, and related autoimmune disorders. Immunovant Inc. operates within the biopharmaceutical sector and is positioned as a specialist in FcRn-based immunology research, with an emphasis on advancing therapies that address the complex biology of autoimmune disease.

CEO Dr. Eric Venker M.D., Pharm.D. · 315 employees · United States · https://immunovant.com